GTx, Inc. (Nasdaq: GTXI) announced in June 2010 that Ostarine™ (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator (SARM), MK-3984, in postmenopausal women.
This was the third Ostarine clinical study that measured lean body mass and physical performance endpoints, and Ostarine has consistently demonstrated the ability to increase muscle mass and strength.
After 12 weeks of treatment in post menopausal women, Ostarine 3 mg and MK-3984 significantly increased total lean body mass. Compared to placebo, mean differences from baseline for lean body mass were observed with increases of 1.54 kg (about 3.4 pounds) for both Ostarine 3 mg and 50 mg of MK-3984 and an increase of 1.74 kg (3.8 pounds) for 125 mg of MK-3984.
Mean leg muscle strength at 12 weeks for Ostarine 3 mg treated subjects increased by 22 pounds from baseline. Old women were able to increase their leg press by 22 pounds.
An 80-year-old might have 30 percent less muscle mass than a 20-year-old. And strength declines even more than mass. Weight-lifting records for 60-year-old men are 30 percent lower than for 30-year-olds; for women the drop-off is 50 percent.
Geriatric specialists are now trying to establish the age-related loss of muscles as a medical condition under the name sarcopenia, from the Greek for loss of flesh. Simply put, sarcopenia is to muscle what osteoporosis is to bone.
We should not accept muscle loss (sarcopenia) any more than we accept bone loss (osteoporosis) and we should treat it. It will enable us to live longer and healthier lives and reduce the cost of healthcare on society.
If you liked this article, please give it a quick review on Reddit, or StumbleUpon. Thanks
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.